Recently, the FDA has approved additional compounds such as novel taxane chemotherapeutic cabazitaxel [6], androgen synthesis inhibitor abiraterone acetate [7], AR signaling inhibitor enzalutamide [8], immunotherapeutic sipuleucel-T [9], and bone micro-environment-targeted radiopharmaceutical alpharadin (Radium-223) for treating CR PCa [10]. Here, AR is linked to posterior cortical atrophy.